Tag: Aptevo Therapeutics

December 13, 2018

Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the first patient...
May 10, 2018

Aptevo Therapeutics Reports First Quarter 2018 Financial Results

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and...
May 8, 2018

New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, and Alligator Bioscience (Nasdaq Stockholm:ATORX), a...
April 16, 2018

Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the presentation of new data...
March 13, 2018

Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today reported its financial results for...
August 17, 2017

Aptevo Therapeutics and Alligator Bioscience Prepare for IND Development

Aptevo Therapeutics and Alligator Bioscience announced they have initiated CMC activities for the manufacturing of clinical material in preparation for...
June 7, 2017

Aptevo Therapeutics Presents Key Features of ADAPTIR

Aptevo Therapeutics revealed new information of its ADAPTIR protein therapeutic platform at two medical conferences.